Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib for Bleeding in Hereditary Haemorrhagic Telangiectasia
NCT02204371Phase 2Terminated
- Sponsor
- GSK
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of pazopanib in hereditary hemorrhagic telangiectasia (HHT), sponsored by GSK. Started Feb 2015; status: terminated.
02
Drugs
pazopanib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT02204371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204371.